NCT00503477View on ClinicalTrials.gov

A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in Japan

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

July 31, 2007

Study Completion Date

January 31, 2009

Conditions
Advanced Solid Tumor
Interventions
DRUG

AZD2171

oral tablet

Trial Locations (2)

Unknown

Research Site, Shizuoka

Research Site, Tokyo

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY